Overview
- ImmunityBio, which filed a formal promotional‑compliance response Monday, saw its shares gain about 3% after the submission.
- The FDA’s advertising office warned on March 13 that a TV spot and a podcast were misleading, and the company says the TV ad never aired and has taken down the podcast.
- Management says it has begun corrective steps that include mandatory executive training, tighter Promotional Review Committee checks, and outside regulatory counsel for high‑visibility communications.
- Multiple law firms have now filed securities class actions covering January 19 to March 24, 2026, with a May 26 deadline to seek lead‑plaintiff status, following a roughly 21% share drop on March 24 when the FDA letter became widely reported.
- Interim results from the 366‑patient QUILT‑2.005 study support a planned supplemental FDA filing in Q4 2026 for a broader bladder‑cancer use, even as analysts note the FDA matter appears to be a promotion‑compliance issue typically resolved through remediation.